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Summary Little is known about the altered lipid metabolism-related transcriptional events in
sebaceous glands of patients with acne vulgaris. Peroxisome proliferator-activated
receptor (PPAR)c, a lipid-activated transcription factor, is implicated in differentia-
tion and lipid metabolism of sebocytes. We have observed that PPARc and its target
genes, ADRP (adipose differentiation related protein) and PGAR (PPARc angioprotein
related protein) are expressed at lower levels in sebocytes from patients with acne
than in those from healthy controls (HCs) Furthermore, endogenous PPARc activa-
tor lipids such as arachidonic acid-derived keto-metabolites (e.g. 5KETE, 12KETE)
are increased in acne-involved and nonacne involved skin of patients with acne,
compared to skin from healthy individuals. Our findings highlight the possible anti-
inflammatory role of endogenous ligand-activated PPARc signaling in human sebo-
cyte biology and suggest that modulating PPARc- expression and thereby signaling
might be a promising strategy for the clinical management of acne vulgaris.
Introduction
Peroxisome proliferator-activated receptor (PPAR)c is
a lipid-activated nuclear hormone receptor that plays
a role in sebaceous lipogenesis, differentiation and
inflammation.1–3 Sebaceous glands (SG) express
PPARc, and various eicosanoids can activate this tran-
scriptional factor in vitro.2,3 This results in raised lipid
production, as shown in SZ95 sebocytes.3 However, it
is not known what role PPARc expression, endoge-
nous PPARc ligands and PPARc-mediated signaling
play in acne-involved sebaceous glands.
To address these issues, focusing on expression levels
of PPARc in acne vulgaris, we systematically examined
the expression pattern of this transcription factor in sebo-
cytes using immunohistochemistry. We also assessed
in situ laser-micro dissected SGs from fresh frozen human
skin tissue biopsies and determined mRNA expression
levels of the PPARc gene and its target genes, adipose dif-
ferentiation related protein (ADRP) and PPARgamma
angioprotein related protein (PGAR). In addition, we
measured eicosanoid levels in SGs from the skin of
patients with acne and of healthy controls (HCs) Patients
with acne had low PPARc expression and signalling
activity, and increased levels of various eicosanoids with
PPARc-activation potential, Therefore, it is reasonable to
speculate that specific PPARc-activating eicosanoids
might have important roles in acne pathomechanism.
Methods
The study was approved by the research ethics com-
mittee of University of Debrecen, and adhered to the
guidelines of the Declaration of Helsinki. All patients
provided informed consent 2.
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Skin biopsies
Patients were examined according to the Global Acne
Grading System Score (GAGS) to evaluate the severity
of acne vulgaris.4 Patients selected for biopsy had
GAGS grade 1 (mild) acne; in total, nine patients with
acne vulgaris provided biopsy tissue. The biopsies were
taken from the upper back; both from acneic papules
on acne-involved skin (AS) and from nonacne-
involved skin (NAS). Skin biopsies were also taken
from five age-matched HCs as reference (Fig. 1a,b).
Isolation of eicosanoids
Previously we found that administration of various
PPARc-activating eicosanoids significantly increased
the expression levels of PGAR and ADRP.3 Selected
PPARc-activating eicosanoids may play an important
role in the pathogenesis of acne vulgaris.1.2 In the pre-
sent study, we determined the level of various PPARc-
activating eicosanoids in skin biopsies from patients.
For quantitative determination of various eicosanoids
and docosanoids we used analytical sample prepara-
tion and determination based on an established high
performance liquid chromatography–tandem mass
spectrometry method used for retinoid quantification,54
which was recently used in a published report on eico-
sanoid and docosanoid analysis for organs and serum
analysis.6 Owing to the limited amount of tissue avail-
able, we pooled three skin samples from HCs, and
compared these with three pooled AS acne and three
pooled NAS acne samples from three patients. Two
sets of data were analysed.
Results
Peroxisome proliferator-activated receptor -c and its
target genes are expressed in situ both in normal
sebaceous glands, and in the acne-involved and
nonacne-involved sebaceous glands of patients with
acne
Immunolabelling identified PPARc protein expression
predominantly in the nuclei of normal SGs obtained
from HCs (3+), but expression was lower in SG cells of
patients with acne, both in AS and NAS samples as
well.
SGs were isolated in situ from the cryosection sam-
ples by laser-microdissection,3 and mRNA level of
PPARc was examined from the collected cells using
real-time quantitative PCR (qPCR). The expression of
PPARc mRNA was higher in SGs from HCs than in
AS or NAS samples (Fig. 1c).
It is generally accepted that PPARc activity is indi-
cated by mRNA expression of its target genes such as
ADRP or PGAR, as established in other cell types.7 We
also found that laser-microdissected SG samples from
HCs expressed ADRP and PGAR mRNA at higher levels
than SGs in AS or NAS samples from patients with acne
(Fig. 1c). These data suggest that PPARc and its target
genes are present in healthy SGs of patients with acne
and also in SGs of age-matched HCs.
Various eicosanoids are present and increased in the
skin of patients with acne
The level of PPARc-activating eicosanoids was lowest
in healthy skin samples, while NAS acne skin samples
had higher levels, and AS acne samples had the high-
est level of eicosanoids (Fig. 1d). This suggests that the
level of PPARc-activating eicosanoids is sufficient or
even excessive in the SGs of patients with acne, maybe
due to the low level of PPARc and reduced feedback
regulation in SG samples from patients with acne.
Discussion
We found that PPARc and its target genes ADRP and
PGAR were expressed at lower levels in sebocytes of
AS from patients with can compared with those from
healthy individuals. Interestingly, the receptor and its
targets were detected at low levels in NAS SGs from
patients with acne. These results appear to be consis-
tent with the established anti-inflammatory role of
PPARc8 and indicate that the inflammatory milieu is
likely to contribute to reduced receptor levels and sig-
nalling.
Previously we showed that selected PPARc-activat-
ing eicosanoids were able to initiate PPARc signalling
in SZ95 sebocytes.3 We demonstrated that the same
compounds are present in acne-affected skin and that
their levels are increased. Therefore, it is tempting to
speculate that this might be part of feedback regula-
tion. However, other lipids or cytokines might con-
tribute to regulation as well.1 Nevertheless, our
findings suggest that PPARc might play a protective
role in normal human sebocytes against excessive lipid
accumulation and induction of inflammatory
responses. In the skin of patients with acne, PPARc
expression was lower or even absent in inflamed and
NAS sebaceous glands; this appears to be a major
feature and may be the reason behind dysregulated
lipid homeostasis and inflammation. Alestas et al.
reported that increased level of the eicosanoids
prostaglanding E3 and leucotriene (LT)B4 were
ª 2015 British Association of Dermatologists2 Clinical and Experimental Dermatology
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detected in arachidonic acid (AA)-treated SZ95 sebo-
cytes, and enzymes that regulate production of these
eicosanoids (LTA4 hydrolase, 5-lipoxygenase and
cyclooxygenase-2), were increased in SGs of AS skin of
patients with mild or moderate acne, but not in SGs
from NAS skin or in SGs from HCs.
These results suggest that the enzymatic machinery
for functional leucotriene and prostaglandin pathways
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Figure 1 (a,b,c) Comparative protein and
mRNA expression patterns of peroxisome
proliferator-activated receptor (PPAR)c in
human normal sebaceous glands (SGs)
from healthy individuals (Ctrl) (n = 5),
and acne-involved (AS) SGs (n = 9) and
nonacne invoved (NAS) SGs (n = 9) from
acne patients. (a,b) Immunohistochem-
istry with tyramin amplification-based
immunostainingm counterstained with
methyl-green or Meyers haematoxylin,
then evaluated semi-quantitatively for %
of PPARc-positive (black arrow) sebo-
cytes of SGs, -, negative; 1+, 0–20%; 2+,
20–50%; 3+, 50–75%; 4+, 75–100%. (c)
Laser-capture microdissection of SG cells,,
with mRNA expression determined by
reverse transcription3 quantitative PCR for
PPARc, and PPARc angioprotein related
protein (PGAR) and adipose differentia-
tion related protein (ADRP). Both protein
and mRNA expression of these molecules
were decreased in AS and NAS samples
of compared with Ctrl samples. Data were
analysed using a two-tailed unpaired t-
test, and *P < 0.05 values were regarded
as significant. In addition, statistical dif-
ferences were further verified using one-
way ANOVA with Bonferroni and Dun-
nett post hoc tests, resulting in similar
results. In real-time quantitative PCR
experiments, the mean and SD were cal-
culated for both the normalized and the
normalizer values for all experiments.
The results were normalized to the
human cyclophyllin gene. Data shown
are mean  SD of five or nine indepen-
dent determinations performed in tripli-
cate. P < 0.05 vs control. (d) High
performance liquid chromatography–tan-
dem mass spectrometry (HPLC MS-MS)
analysis of eicosanoids in whole skin
samples: Ctrl, AS and NAS. Eicosanoids
were elevated in NAS and even higher in
AS, compared with controls. Three sam-
ples were pooled and measured. Heat
map of concentrations; colour bar defines
concentration fold change. Two sets of
samples were measured in triplicate, data
shown are the average result of one set
of samples.
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are active in sebocytes, and that the enzymes that
regulate these pathways are increased in AS SGs. It
is possible that PPARc is a key molecule in negative
feedback regulation as an anti-inflammatory molecule
and that when PPARc level and activity is low, the
negative feedback reaction is turned off, and the
enzyme machinery of inflammation, such asthe leu-
cotriene and prostaglandin pathways, is not inhibited.
It is possible also that under these conditions, produc-
tion of PPARc ligand eicosanoids is not inhibited,
thus the level of these eicosanoids are also raised
compared with healthy SGs. This would be a classic
hormonal regulation. Furthermore, elevation of
PPARc ligand eicosanoids in NAS skin was also
observed in the current study. Based on these data, it
could be speculated that that PPARc is not a sec-
ondary molecule that is downregulated due to inflam-
mation, but rather that it is already low prior to
inflammation, which suggests that downregulation of
PPARc has a causative role in the initiation of the
autoinflammatory reaction in acne vulgaris. Confirm-
ing this theory, it is known that topical application
of the PPARc agonist azelaic acid (AA) produces
anti-inflammatory effects in acne vulgaris.9, In addi-
tion, AA induces PPARc mRNA expression and tran-
scriptional activity in human sebocytes,10 which also
supports the possible anti-inflammatory role of
PPARc in sebocytes.
It has also been reported that PPARc activation
increases lipogenesis.2,3 However, these measure-
ments were carried out in human immortalized sebo-
cyte cultures (Seb-1, SZ95), and the primary cells
were obtained from healthy sebaceous glands, which
express high levels of PPARc. Thus, it is possible
that if PPARc is at a high level, its activation
increases lipid production in healthy SGs. In the pre-
sent study, we observed that PPARc is low in SGs
in both AS and NAS skin of patients with acne.
Therfore, it seems likely that when PPARc is miss-
ing, the inflammatory regulation of SG fails, and
autoinflammatory reactions are turned on. In
addition lipid production in acne SGs is higher than
in healthy SG, which suggests that in AS SG the
primary effect of PPARc might be regulation of
inflammation, and maybe also in maintaining the
balance of lipid production, but not simply the level
of lipids.
Our data clearly show that PPARc levels and sig-
nalling activity are decreased in sebocytes from
patients with acne. This suggests that PPARc might
be a clinical target in affected sebocytes in the man-
agement of acne vulgaris.
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Learning points
• PPARc protein is a transcription factor that is
involved in regulation of lipid metabolism of
sebocytes.
• PPARc protein and mRNA levels are high in
SGs of skin from healthy individuals, but low in
SGs of patients with acne.
• PPARc activity is indicated by the mRNA
expression of its target genes such as ADRP
and PGAR in sebocytes and in other cell types.
• ADRP and PGAR levels –referring to PPARc
activity – are low in SGs of patients with acne,
compared with normal SG.
• PPARc activator ligand eicosanoids are pre-
sented at high levels in the skin of patients with
acne.
• Our data suggest that in normal human sebo-
cytes in healthy individuals, PPARc might play
a protective role against excessive lipid accumu-
lation and inflammatory responses, which
makes this molecule a possible therapeutic tar-
get in acne vulgaris.
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